 |
|
|
| |
Preclinical characterization of PRO 206, an orally active HCV entry inhibitor
|
| |
| |
Reported by Jules Levin
2009 EASL Annual Meeting
April 23, 2009
D. Qian, G. A. Coburn, A. Q. Han, J. M. de Muys, C. Gauss, K. Provoncha, M. Canfield, D. Paul, S. Mohamed, S. Moorji, D. Fisch, J. Murga, Y. Rotshteyn, P. J. Maddon and W. C. Olson
Progenics Pharmaceuticals, Inc., Tarrytown, NY, USA
|
| |
|
|
|
|
|
